Erlocip 150 mg contains Erlotinib, an oral cancer medication that targets specific proteins involved in cancer cell growth. It is used mainly for the treatment of non-small cell lung cancer (NSCLC) and advanced pancreatic cancer. Erlotinib belongs to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, and it works by blocking the signals that encourage cancer cell proliferation.

• Effective in EGFR-mutated NSCLC

• Improves survival rates in pancreatic and lung cancers

• Convenient oral therapy with once-daily dosing

• Delays disease progression in targeted cancer therapy

• Take one tablet orally, once a day

• Administer at least 1 hour before or 2 hours after meals

• Swallow whole with water; do not crush or chew

• Follow the exact regimen prescribed by your oncologist

• Strength: 150 mg of Erlotinib per tablet

• Route: Oral administration

• Typical Dose: One tablet daily or as prescribed

• Dose Adjustment: May be needed based on patient’s response or side effects

• Duration: Based on ongoing response and clinical evaluation

• Not recommended during pregnancy or breastfeeding

• Use with caution in patients with liver or kidney disorders

• Avoid exposure to sunlight; use sunscreen or protective clothing

• Inform your doctor about any other medications or supplements being taken

• Smoking may reduce the effectiveness of Erlotinib; cessation is advised

• Common: Skin rash, diarrhea, fatigue, loss of appetite

• Less Common: Nausea, vomiting, liver enzyme changes, dry skin

• Serious: Interstitial lung disease, gastrointestinal perforation, eye irritation

• Seek medical attention if you experience severe shortness of breath, persistent diarrhea, or jaundice

• Store in a cool, dry place at room temperature

• Keep away from moisture, heat, and direct light

• Keep out of reach of children and pets

• Do not use if the packaging is damaged or past the expiry date

Q1. What is Erlocip 150 mg used for?
A: It is used to treat non-small cell lung cancer and advanced pancreatic cancer, especially in patients with EGFR-positive tumors.

Q2. How does Erlotinib work?
A: It blocks EGFR, a protein that helps cancer cells grow and divide, thereby slowing or stopping tumor growth.

Q3. Can I take it with food?
A: No, take it on an empty stomach — either 1 hour before or 2 hours after a meal.

Q4. What precautions should I take while on Erlocip?
A: Avoid sun exposure, report any breathing problems or skin issues, and ensure regular blood tests to monitor liver function.

Q5. Is it safe to smoke while on Erlocip?
A: No. Smoking reduces the efficacy of Erlotinib. It is strongly recommended to quit smoking during treatment.